Evaluation of the analgesic effect of oral administration of Acetaminophen + Oxycodone after extracorporeal shock with shock waves

Evaluation of the analgesic effect of oral administration of Acetaminophen + Oxycodone after extracorporeal shock with shock waves

A clinical trial with two groups of patients: parallel, therapeutic, blanced block randomization, single blind (patient). 150 patients referred to Sinai Hospital.

150 patients at Sina Hospital. blanced block randomization, single blind(patient). Patients are divided into two groups: Group 1: Acetaminophen 325 + oxycodone 5 + diclofenac suppository (100 mg). Group 2 : Diclofenac suppository (100 mg) + placebo.

Inclusion criteria: ASA≤II, Consent to participate in the study, Kidney stones between 4 and 20 mm, No history of previous open surgery, No history of previous crusher. Exclusion criteria: Increased serum creatinine (more than 2 mg/dL), Urinary tract infection, High grade hydronephrosis, Diabetic, Taking NSAIDs, acetaminophen and acetaminophen codeine in the previous 24 hours History of peptic ulcer, Taking peptic ulcer pills, G6PD deficiency, History of liver and kidney disease, History of drug allergy, drug addiction.

Intervention group 1: Acetaminophen 325 + oxycodone 5 + diclofenac suppository (100 mg) . Intervention group 2: Diclofenac suppository (100 mg) + placebo.

Pain control, Complications, hospitalization time, surgical time, and success rate of complete stone therapy.

The present study is a Single blind randomized clinical trial. For randomization, the balanced block randomization method with blocks of size 4 is used. Intervention group A and control group B have been determined. After the methodologist prepares the randomization sequence using the sealdenvelop online site, the generated sequence will be made available to a technician outside the research team. Quadruple blocks (A or B) are placed inside the envelopes. After the arrival of the first patient with the inclusion criteria, the envelopes are randomly selected and the type of patient group is informed to the research team through a trained technician. The patient is placed in (acetaminophen 325 + oxycodone 5 + diclofenac suppository (100 mg)) or (placebo + diclofenac suppository (100 mg))group based on the randomly selected envelope.

Patients who have expressed their consent to participate in the study after surgery without knowing the existence of two drug groups based on a randomly selected envelope are placed in the treatment group (acetaminophen 325 + oxycodone 5 + diclofenac suppository (100 mg)) or Placebo + diclofenac suppository (100 mg).

demographic information anonymously

one year after publication

Researchers working in academia, physicians, surgeons and hospitals

Any analysis can be done with the consent of the main researcher

Sina Hospital, Urology Research Center, Head of Urology Research Center: Dr. Seyed Mohammad Kazem Aghamir 00982166348560

After reviewing the information by the administrator and epidemiologist, the patient information will be available for the applicant by the provision of a patient's privacy.

-